Skip Ribbon Commands
Skip to main content
releases

Releases

 

SER=Stock exchange release          PR=Press release

 

Select year:  

2013-06-04 SER Biotie purchases option to acquire Neurelis, Inc.
2013-05-10 SER Biotie announces start of clinical study with nepicastat (SYN117) in cocaine dependence
2013-05-06 SER Biotie: Selincro launched in the United Kingdom
2013-05-06 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2013-05-03 SER Biotie interim report 1 January - 31 March 2013
2013-04-22 SER Biotie: Selincro launched in first European markets
2013-04-04 SER RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP. AND ORGANIZATION OF THE BOARD
2013-03-21 SER Biotie Presents Tozadenant Phase 2b data at AAN Annual Meeting
2013-03-07 SER Biotie's Annual Financial Report and Corporate Governance Statement 2012 published
2013-03-04 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2013-02-28 SER Biotie: Selincro (nalmefene) receives European marketing authorization
2013-02-28 SER INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.
2013-02-28 SER Biotie financial statement report 1 January - 31 December 2012
2013-02-28 SER Biotie updates outlook - non-cash impairment charge for ronomilast
2013-02-27 SER Amendment to the release on UCB license of worldwide rights to tozadenant in Parkinson's disease from Biotie
2013-02-26 SER Biotie: UCB to license worldwide rights to tozadenant in Parkinson's disease from Biotie
2013-02-04 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2013-01-03 SER Change in the number of votes relating to Biotie Therapies Corp.'s shares
2013-01-02 SER David Cook appointed Chief Financial Officer of Biotie